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Endoscopic ultrasound (EUS)-guided interventions for treatment of periluminal tumors allows for a minimally invasive alternative to other more invasive
methods of tumor therapies such as surgery or percutaneous ablation. For many tumors, especially pancreatic and peripancreatic tumors, EUS allows the
most direct access for providing therapy. However, our experience with EUS-guided tumor ablation therapy remains limited. Several promising methods
for EUS-guided ablation are in development or undergoing clinical evaluation. There have been case reports and several limited studies evaluating various
injection therapies such as alcohol or biologic agents. In addition, laser, photodynamic therapy, radiofrequency ablation, and high-intensity focused
ultrasound are currently being investigated as possible modalities for EUS-guided ablation. These methods for performing EUS-guided ablation are
reviewed.
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Endoscopic ultrasound (EUS) has expanded into a therapeutic as
well as diagnostic tool since it was ﬁrst introduced more 30 years
ago. Linear EUS has made it possible for endoscopists to sample
speciﬁc lesions with ﬁne needle aspiration. Furthermore, modal-
ities for EUS-guided therapy are expanding. These modalities are
especially valuable for elderly and high-risk patients in whom
pancreatic surgery may be considered too high risk.
EUS-guided ﬁne-needle injection
Pancreatic cysts are increasingly being discovered incidentally
as the use of cross-sectional imaging becomes more common. In
one autopsy study, the prevalence was estimated to be 25%.1 For
pancreatic cysts with malignant potential, surgical resection re-
mains the mainstay of therapy, although with substantial
morbidity. EUS with ﬁne needle aspirationwas ﬁrst introduced as a
diagnostic modality in 1992 when the advent of linear-array EUS
allowed for direct sampling of a pancreatic cyst under ultrasound
guidance.2 The subsequent development of EUS-guided ﬁne needle
injection (EUS-FNI) is currently being investigated as a possible
nonsurgical method for managing pancreatic cysts.
EUS-guided ethanol ablation has previously been shown to be
effective in renal, hepatic, and thyroid cysts by leading to cell
membrane lysis. The ﬁrst published series of using ethanol lavage
of pancreatic cystic lesions was published in 2005. In this study,
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quently, a randomized controlled trial showed signiﬁcant size
reduction in patients who underwent ethanol lavage compared to
saline lavage, with complete resolution of the cyst in 33.3% of pa-
tients.4 DiMaio et al5 demonstrated greater size reduction and rate
of cyst resolution with two treatments of ethanol lavage compared
to one. EUS-guided ethanol lavagewith paclitaxel injection has also
been reported as a safe and effective alternative to ethanol injection
alone.6,7 Ethanol has also been used for ablation of metastatic
lymph nodes and other pancreatic lesions such as insulinomas,
although these modalities have not yet been studied in clinical
trials.8,9
EUS-FNI has been used to inject donor and host mononuclear
cells into pancreatic adenocarcinomas on the theory that it will
stimulate an immune response and cytokine release to slow tumor
progression. Although the procedure appeared to be safe in a Phase
I trial in eight patients, it has not been replicated or proven to be
clinically beneﬁcial.10
TNFerade is an adenoviral vector containing the human TNF-
alpha gene, which is thought to slow tumor progression.11
Although initially proven to be safe and effective when injected
into pancreatic adenocarcinoma by EUS or percutaneously, a sub-
sequent Phase III clinical trial failed to show a statistically signiﬁ-
cant beneﬁt in tumor suppression and was stopped early.12,13 Safety
and efﬁcacy have also been shown in a single trial of esophageal
cancer.14
We also reported a case study of EUS-FNI delivery of interferon
b-1B into a peripancreatic tumor followed by systemic T cell infu-A, USA
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Fig. 1. Prototype EUS-guided HIFU endoscopy. The device consists of an ultrasound
imaging transducer (white arrow) and a spherically curved piezoelectric ceramic HIFU
transducer (white arrowhead). EUS, endoscopic ultrasound; HIFU, high-intensity
focused ultrasound.
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cinoma, a highly aggressive neuroendocrine skin malignancy.15 The
drug had previously been administered systemically, but had failed
to reach the lesion in sufﬁcient concentration. Through EUS-FNI,
the drug was able to be delivered directly into the tumor site,
resulting in a signiﬁcant reduction in the tumor size.
EUS-guided radiofrequency ablation
EUS-guided radiofrequency ablation (RFA) uses high-frequency
alternating current to cause a thermal-induced coagulative necro-
sis. Although used commonly in liver, kidney, and prostate cancers,
its utilization in pancreatic cancers has been limited by its retro-
peritoneal location. Advances in RFA electrodes have created a
potential for its use as a palliative and curative tool. EUS-guided RFA
was ﬁrst studied in an animal model by Goldberg et al16 in 1999,
when they used it to complete coagulation necrosis in a porcine
pancreas. In 2009, Varadarajulu et al17 reported on EUS-guided RFA
of the liver in a porcine model with successful coagulation necrosis
of the targeted areas. Radiofrequency has also been combined with
simultaneous cryogenic cooling and been shown to be effective and
with fewer complications than radiofrequency alone in a porcine
pancreas, liver, and spleen.18,19 Kim et al20 recently reported the
safe and effective use of an 18-gauge RFA electrode to directly
puncture a porcine pancreas under EUS guidance.20 They demon-
strated successful tissue ablation in a spherical distribution in 10
pigs with no procedure-related complications. Of note, only the
body and tail of the pancreas was targeted.
EUS-guided laser therapy
Photodynamic therapy (PDT) has been shown to be effective at
inducing coagulation with the photosensitizing agent porﬁmer
sodium. EUS-guided PDTwas ﬁrst described by Chan et al21 in 2004
as an effective form of tissue ablation in porcine liver, pancreas,
kidney, and spleen. After inserting a 19-gauge needle into the target
organ, they passed a quartz optical ﬁber through the needle to
deliver the PDT directly into the organ. Yusuf et al22 demonstrated
effectiveness using PDT with verteporﬁn, as it has been associated
with less photosensitivity than porﬁmer sodium. They performed
EUS-PDT using a porcine pancreas model, varying the amount of
time the pancreas was exposed to the laser therapy, and found
increased amounts of tissue ablation as the duration of laser ther-
apy was increased.
The neodymium:yttrium aluminum garnet (Nd:YAG) laser is a
more recent development in EUS-guided laser therapy. Di Matteo
et al23 initially reported on EUS-guided Nd:YAG delivering between
500 J and1000 Jof energy inaporcinepancreaswithnocomplications
and successful tissue ablation on pathology. Later, the same group
reported the successful application of Nd:YAG therapy to a hepato-
cellular carcinoma.24 More recently, Di Matteo et al25 studied the
optimal setting of laser by comparing a range of laser output powers
from 1.5 W to 20 W, again in a porcine pancreas model, measuring
tissue ablation volume and carbonization volume, ameasure thought
to approximate risk of thermal injury to surrounding tissues. They
found that as the laser output power is increased from 1.5W to 20W,
the carbonization volume increases constantly, whereas the tissue
ablationvolumeplateaued between10Wand20W. Thismodel could
be an effective tool for determining safe but effective therapeutic
doses of Nd:YAG laser in future studies.25
EUS-guided brachytherapy
Brachytherapy is a type of radiation therapy where the radia-
tion source is inserted directly into or adjacent to cancer tissue.Although brachytherapy has been studied extensively in the
treatment of many cancers, its use in pancreatic adenocarcinoma
is still investigational. The largest clinical trial included 15 pa-
tients, and demonstrated improvement in pain for a limited
period.26 However, there was no survival beneﬁt and local com-
plications (pancreatitis and pancreatic pseudocyst formation)
occurred in three of the 15 patients. Larger studies have not yet
been performed to conﬁrm these ﬁndings or demonstrate survival
beneﬁt.
EUS-guided high intensity focused ultrasound
High-intensity focused ultrasound (HIFU; Fig. 1) is a rapidly
developing technology that is becoming more widely used for
noninvasive and minimally invasive ablation of benign and malig-
nant tumors. This therapy was ﬁrst reported by Prat et al,27 who
demonstrated effective ablation in an animal model. A more recent
prototype EUS-guided HIFU endoscope has been developed using
an endobronchial ultrasound transducer for image guidance with
overall dimensions that allow the device to be passed through the
oropharynx into the stomach.28 HIFU works by delivering ultra-
sound energy to the tumor bed, leading to an elevation in tissue
temperature and subsequently tissue denaturation.29 Recent
studies suggest that the unique mechanical effects of HIFU may
help to enhance targeted drug delivery and stimulate an antitumor
immune response in many tumors including pancreatic tumors.30–
32 HIFU is potentially beneﬁcial both for curative and palliative
treatments for pancreatic cancer, and has been shown to safely
reduce pain in patients with unresectable pancreatic cancer, with
pain relief achieved in up to 87.5% of patients treated with extra-
corporeal HIFU.33,34 However, targeting periluminal tumors using
an extracorporeal source is often not possible owing to the lack of
an adequate acoustic window because of the presence of overlying
bowel gas. The development of an EUS-guided HIFU transducer has
many potential beneﬁts including improved targeting, decreased
energy requirements, and decreased potential for injury to inter-
vening structures.
Conclusion
Since its development as a purely diagnostic technique 30 years
ago, EUS has undergone an expansion into the therapeutic realm.
EUS-guided ablative therapies are increasingly being used in clin-
ical settings and studied in preclinical settings. Clearly, there is a
need for a minimally invasive tool that is able to deliver therapy in
Alexander R. Ende and Joo Ha Hwang / EUS-guided tumor ablation 29close proximity to the lesion. These tools are especially beneﬁcial
for patients at high risk for surgery and for therapies with poten-
tially high morbidity.
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